Sickle cell disease

Sickle cell disease
Name	Sickle cell disease
Field	Hematology
Symptoms	Anemia, pain crises, infections, organ damage
Complications	Stroke, acute chest syndrome, splenic sequestration
Onset	Childhood
Duration	Lifelong
Causes	Inherited hemoglobin mutation
Diagnosis	Blood tests, genetic testing
Treatment	Hydroxyurea, transfusion, bone marrow transplant, gene therapy

Sickle cell disease is a hereditary hemoglobinopathy characterized by chronic hemolytic anemia, episodic vaso-occlusive pain crises, and multi-organ complications. It affects individuals across Africa, the Americas, Europe, and the Middle East and interacts with global health initiatives and organizations addressing genetic disorders. Clinical care spans pediatric and adult specialties, involving hematology clinics, transplant centers, and public health programs.

Signs and symptoms

Patients commonly present with severe episodic pain, chronic anemia, jaundice, and pallor, often prompting evaluation in emergency departments and specialty clinics affiliated with institutions like Mayo Clinic, Johns Hopkins Hospital, Great Ormond Street Hospital, Massachusetts General Hospital, and Cleveland Clinic. Recurrent vaso-occlusive crises can cause acute chest syndrome, pulmonary complications managed by teams including intensivists from Royal Brompton Hospital and stroke units such as those at Mount Sinai Health System; these events may necessitate transfusions coordinated by services like the American Red Cross and blood banks at St. Jude Children's Research Hospital. Splenic dysfunction predisposes to infections with encapsulated organisms, requiring prophylaxis and immunizations recommended by bodies like the World Health Organization and national agencies including the Centers for Disease Control and Prevention and the National Health Service. Chronic organ damage may involve the kidneys, eyes, and bones, leading to complications managed by nephrology services at Charité – Universitätsmedizin Berlin and ophthalmology centers such as Bascom Palmer Eye Institute. Psychosocial burden engages community organizations like United Nations Children's Fund initiatives, patient advocacy groups similar to Sickle Cell Disease Association of America, and social services linked with hospitals like Seattle Children's Hospital.

Genetics and pathophysiology

The disorder results from a mutation in the beta-globin gene (HBB) producing hemoglobin S; molecular genetics and evolutionary context are studied in centers such as Harvard University, University of Oxford, University of Cambridge, and Stanford University. Heterozygote advantage with protection against severe malaria has been investigated by researchers associated with the Wellcome Trust, London School of Hygiene & Tropical Medicine, Centers for Disease Control and Prevention, and the Rockefeller University. Pathophysiology involves polymerization of deoxygenated hemoglobin S, red cell sickling, microvascular occlusion, and hemolysis, subjects explored in laboratories at National Institutes of Health and university departments like University of California, San Francisco. Gene-editing and curative strategies, including CRISPR approaches, are pursued in clinical research programs at NIH Clinical Center, Dana-Farber Cancer Institute, Fred Hutchinson Cancer Center, and biotech collaborations with institutions such as Broad Institute and Regeneron. Historical molecular work links to figures and institutions like Linus Pauling and California Institute of Technology.

Diagnosis

Diagnosis relies on hemoglobin electrophoresis, high-performance liquid chromatography, newborn screening programs exemplified by initiatives in United States Department of Health and Human Services, National Health Service (England), and state public health laboratories, as well as genetic testing available via academic centers like Mayo Clinic and commercial providers. Imaging for complications uses modalities developed at Johns Hopkins Hospital and Massachusetts General Hospital and stroke risk is assessed by transcranial Doppler programs modeled on protocols from Children's Hospital of Philadelphia and St. Jude Children's Research Hospital. Prenatal diagnosis and counseling are offered in referral centers such as Karolinska Institutet and Sheffield Teaching Hospitals with input from genetic counseling services affiliated with University College London and University of Toronto.

Treatment and management

Disease-modifying therapy includes hydroxyurea regimens informed by trials conducted at National Institutes of Health and cooperative groups like the National Institutes of Health Clinical Center and Children's Oncology Group. Chronic transfusion programs and iron chelation are provided at hematology units in hospitals such as Royal Free Hospital and Guy's and St Thomas' NHS Foundation Trust. Curative options include allogeneic hematopoietic stem cell transplantation performed at centers like Fred Hutchinson Cancer Center, Great Ormond Street Hospital, and St. Jude Children's Research Hospital, and emerging gene therapy trials at Dana-Farber Cancer Institute, UCLA Health, and University of Pennsylvania. Supportive care integrates pain management protocols from tertiary centers (e.g., Brigham and Women's Hospital), infection prophylaxis per World Health Organization guidance, and multidisciplinary rehabilitation programs exemplified by collaborations with institutions like MossRehab and Shepherd Center. Health systems implement newborn screening, comprehensive care models, and transition programs linking pediatric centers such as Children's Hospital of Philadelphia with adult services like Brigham and Women's Hospital.

Epidemiology and public health

Prevalence is highest in sub-Saharan Africa, parts of the Mediterranean, the Middle East, India, and among diaspora populations in the Americas and Europe; surveillance and control efforts involve World Health Organization, national ministries of health, and non-governmental organizations like Bill & Melinda Gates Foundation and Clinton Health Access Initiative. Newborn screening programs in countries such as United States, United Kingdom, Brazil, and Nigeria shape early detection strategies; public health responses include vaccination campaigns coordinated with agencies like GAVI, the Vaccine Alliance and emergency response planning linked to United Nations. Health equity, access to curative therapies, and newborn screening scale-up are priorities in global health policy discussions at forums like the World Health Assembly.

History and society

Clinical description and molecular elucidation involved contributions from physicians and scientists associated with institutions like John Hopkins University School of Medicine, Harvard Medical School, University of Pennsylvania, and Stanford University School of Medicine; landmark publications and advocacy efforts have been amplified by organizations such as Sickle Cell Disease Association of America and international patient groups. Public figures and cultural works addressing the disease include engagements by advocacy leaders and media outlets such as BBC, The New York Times, and The Guardian, while ethical, legal, and social implications are debated in forums like United Nations panels and academic conferences at Yale University and University of Chicago. Advances in therapy reflect collaborations across academia, philanthropy, and industry, with translational milestones reported from centers like Broad Institute and Rockefeller University.

Category:Genetic disorders